A randomized, naturalistic cost-effectiveness study in a managed health care setting

Author： Heiligenstein J.H.   Simon G.  

Publisher： Elsevier

ISSN： 0924-977X

Source： European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 256-257

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting: Olmesartan Medoxomil Compared with Losartan, Valsartan, and Irbesartan

By Simons W.R.  

PharmacoEconomics, Vol. 21, Iss. 1, 2003-01 ,pp. : 61-74

Adis International

Access to resources Recommend Favorite

The Prevalence of Chromium Allergy in the United States and Its Implications for Setting Soil Cleanup: A Cost-Effectiveness Case Study

By Proctor D.M.   Fredrick M.M.   Scott P.K.   Paustenbach D.J.   Finley B.L.  

Regulatory Toxicology and Pharmacology, Vol. 28, Iss. 1, 1998-08 ,pp. : 27-37

Academic Press

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine: The Disability in Strategies for Care (DISC) Study

By Sculpher M.  

PharmacoEconomics, Vol. 20, Iss. 2, 2002-02 ,pp. : 91-100

Adis International

Access to resources Recommend Favorite

Valuing Health States for Use in Cost-Effectiveness Analysis

By Brazier John  

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 769-779

Adis International

Access to resources Recommend Favorite

Rofecoxib cost-effectiveness study results debated

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 455, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite